HARROW, INC.
No SEC Form 4 filings for $HROW in the last 30 days.
Royce & Associates LP reduced its Harrow, Inc. (NASDAQ:HROW) stake by 4.4% in Q4, selling 23,267 shares to hold 509,746 shares worth about $24.98M, per its SEC disclosure. Harrow reported May 11 EPS of -$0.74 vs -$0.43 consensus and revenue of $44.2M vs $52.43M. Analysts’ average target is $69.43.
An Opaleye-managed account recently sold 5,000 shares of Harrow (HROW) common stock at $54.18 per share on February 27, 2026, as reported in a Form 4 SEC filing. Following this transaction, the managed account holds 65,000 shares, while Opaleye, L.P. directly owns an additional 3,815,000 shares. Opaleye Management Inc. disclaims beneficial ownership beyond its pecuniary interest in these shares.
Harrow, Inc. (HROW) reported record revenues of $272.3 million in 2025, marking a 36% increase, primarily driven by strong growth in branded products. The company also significantly narrowed its net loss to $5.1 million. Strategic moves included the acquisition of Melt Pharmaceuticals, expansion of its branded portfolio, and a complete debt refinancing, positioning HROW for future growth with new product launches and a strong cash reserve.
